These findings highlight the potential of integrating immunotherapies with traditional chemotherapy or emerging treatments, like PARP inhibitors, personalized neoantigen vaccines, adoptive cell transfer, and modulators of the tumor microenvironment (TME), to improve treatment outcomes in pancreatic cancer. Here, PARP1 is linked to familial pancreatic carcinoma.